WinstonWınston
TherapeuticsMD logo

TherapeuticsMD

TXMD
51
Drug Manufacturers - Specialty & Generic · Healthcare
Winston Score
51
Winston is curious
Mixed quality — meaningful strengths and weaknesses.

TherapeuticsMD is a small pharmaceutical company focused on women's health. It develops and sells prescription medicines designed to treat conditions related to menopause, such as hot flashes and vaginal discomfort. Its main product is Annovera, a year-long contraceptive vaginal ring, along with hormone therapy drugs sold under the Bijuva and Imvexxy brand names.

The company makes money by selling these prescription drugs to pharmacies and healthcare providers across the United States. Despite a high gross margin above 90%, TherapeuticsMD spends far more than it earns, resulting in deep operating losses — a sign it is still trying to build a sustainable commercial business. The company has a narrow focus on a specific patient population, which limits its market size but also keeps competition somewhat contained. The biggest risk is whether it can grow revenue fast enough to stop burning through cash before needing to raise more money or restructure.

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+84.2% YoY

YoY Growth Rate

Strong revenue growth

EPS Growth

+114.5% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

6.9%ownership

Flat

Insiders holding steady — not selling despite ability to

Cash Position

Cash flow positive

$8M cash & investments

Company generates more cash than it spends — no dilution risk from fundraising

Strong grower

TherapeuticsMD is growing revenue at 84% year-over-year. The Winston Score penalises unprofitable companies, but revenue at this pace tells a different story — this is a company still in "build mode."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
55.1%
Premium pricing power — 55.1% gross margin
Operating Margin
-99.9%
Losing money on operations — -99.9%
ROCE
-2.3%
Weak — -2.3% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
+82.1%
Fast-growing sales (82.1% YoY)
EPS YoY
N/A
Data not available
EPS Consistency
6/8 quarters
Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
1494%
Turns 1494% of profit into real cash
FCF Margin
79.7%
Converts sales into free cash efficiently (79.7%)

Free cash flow margin above 20%. Out of every $100 in sales, more than $20 is real cash they keep.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
0.18
Conservative — low debt load (0.18)
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
126.0x
no trend
Expensive — P/E 126.0

P/E over 35. The market is pricing in heavy, sustained growth.

P/E vs Forward
+113.6
GROWING
Earnings expected to grow meaningfully — cheaper on forward P/E (126.0 → 12.4)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial